Not a healthcare professional? Go to the patient or caregiver website.

MYLOTARG™ Boxed Warning (gemtuzumab ozogamicin)

WARNING: HEPATOTOXICITY

Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG. (5.1 and 6.1)

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No